2022 Clinical Neuromuscular Pathology Reading List, Learning Objectives, and CME

Reading List

Please click below to access the 2022 Clinical Neuromuscular Pathology reading list.

2022 Clinical Neuromuscular Pathology Reading List »

C-cert Activity Description

The Continuous Certification (C-cert) activities provide subspecialty learning and knowledge assessment to ensure that diplomates are staying up to date on the latest science, treatments, and therapeutics relating to their subspecialty. The annual activities include: 1) reading the subspecialty  journal articles, and 2) taking and passing the 25-question online post-reading quiz to assess knowledge gained from the journal article content. 

Learning Objectives

Upon completion of this UCNS C-cert activity, participants will be able to:
  • Identify clinical and pathological correlates of neuromuscular complications with cancer-related therapy (including checkpoint inhibitors)
  • Review the key indications for muscle and nerve biopsies and recognize key normal findings, artifacts, and histopathological features on muscle and nerve biopsies
  • Correlate clinical, laboratory, and pathological features of immune-mediated and para-infectious (including COVID-19) neuropathies and myopathies
  • Discuss histopathological features in muscle disorders (mitochondrial disorders and congenital myopathies) and the mechanisms of CIDP

Core Competencies

This UCNS C-cert activity covers the following core competency:
  • Medical Knowledge

Continuing Medical Education (CME) Instructions

To claim CME credits, answer question 26 on the quiz to reflect the total time spent completing the required reading and online quiz. This question is not included in the scoring of the quiz. A passing score of 80% of higher is needed to meet C-cert requirements and receive CME credit. CME credit confirmation will be emailed within three weeks of passing the quiz.

ACCME Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of Neurology Institute (AANI) and United Council for Neurologic Subspecialties. The AANI is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Academy of Neurology Institute designates this enduring material for a maximum of 15 AMA PRA Category 1TM credit(s). Physicians should claim only their credit commensurate with the extent of the participation in the activity.

ABPN Self-Assessment Designation Statement

The American Board of Psychiatry & Neurology (ABPN) has reviewed the UCNS Continuous Certification (C-cert) self-assessment activity and has approved the program as a part of a comprehensive self-assessment (SA) program, which is mandates by the American Board of Medical Specialties as a necessary component of maintenance of certification. The number of ABPN SA credits granted will equal the number of CME hours claimed for the activity. 


The UCNS complies with all standards and policies of the ACCME, including identification and resolution of all conflicts of interest prior to the educational activity being delivered to learners. Accordingly, UCNS  planners, authors, and staff comply with the UCNS’s Conflicts of Interest Policy

2022 C-cert Activity Planner Disclosures
All relevant financial relationships have been mitigated.

Clinical Neuromuscular Pathology Certification Examination Committee Contributors

Mazen Mohammad Dimachkie, MD, Chair, University of Kansas Medical Center
Disclosures: Received personal compensation for consulting services provided to: ArgenX, Catalyst, Cello, Covance, CSL-Behring, EcoR1, Kezar, Momenta, NuFactor, Octapharma, RaPharma/UCB, RMS Medical, Sanofi Genzyme, Shire Takeda, Scholar Rock, Spark Therapeutics, Third Rock and UCB Biopharma; received research grants or contracts from Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, Corbus, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Mitsubishi Tanabe Pharma, MDA, NIH, Novartis, Octapharma, Orphazyme, Ra Pharma/UCB, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark Therapeutics, UCB Biopharma, Viromed/Healixmith and TMA. Compensation/research funded in part by Pharmaceutical. 

Michelle Lynn Mauermann, MD, Vice Chair, Mayo Clinic – Rochester
Disclosures: Receives research support from Alnylam, IONIS, and EIDOS for amyloid clinical trials.

Robert C. Bucelli, MD, PhD, Washington University School of Medicine in St. Louis
Disclosures: Holds equity in Neuroquestions.com, a board review website, and receives K-1 income from site on annual basis. Received compensation for serving on advisory board and as a steering committee member for Biogen; provided review of case for a defense lawyer as an expert witness.

Ahmed Mohamed Attia El-Dokla, MD, Neuromuscular Clinic at Upstate Bone & Joint
Disclosures: Nothing to disclose.

Shalini Mahajan, MD, Cedars-Sinai Medical Center
Disclosures: Nothing to disclose.

Raghav Govindarajan, MD, St. Elizabeth Medical Group, Illinois
Disclosures: Received compensation from Alexion (consulting and speaking), UCB (consulting), Biohaven (consulting and speaking), MT pharma (consulting and speaking), Catalyst (consulting and speaking), Argenx (consulting), Roche (consulting), Sarepta (consulting), Amicus (consulting); received compensation for serving on advisory boards for: MGFA, MGA, ALSA. Served in editorial role for Alexion and UCB, and as researcher for Band of Hope foundation, with funding for clinical trial poly MVA in ALS. 

Margherita Milone, MD, PhD, Mayo Clinic – Rochester
Disclosures: Received internal research funding for research at Mayo Clinic.

Aziz Shaibani, MD, Nerve and Muscle Center of Texas
Disclosures: Nothing to disclose.

Anthony A. Amato, MD, Brigham and Women's Hospital
Disclosures: Received fees while serving as a consultant/medical advisory board for Johnson & Johnson, Argenx, and Serono; received compensation and/or research funding through NIH grant.

Mohamed Kazamel, MD, University of Alabama at Birmingham
Disclosures: Received fees for consulting/speaking for Alnylam Pharmaceuticals; received research funding from NIH Porphyria and Rare Disease Consortium.

Staff Contact

Bryan Hagerla, Continuous Certification Manager
Disclosures: Nothing to disclose.
[email protected]
(612) 928-6326